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Abstract
Background: Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemother-
apy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic
subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy.
Methods: A research-based PAM50 assay was applied in 422 HER2-positive tumors from five II–III clinical trials (SOLTI-
PAMELA, TBCRC023, TBCRC006, PER-ELISA, EGF104090). In SOLTI-PAMELA, TBCRC023, TBCRC006, and PER-ELISA, all patients
had early disease and were treated with neoadjuvant lapatinib or pertuzumab plus trastuzumab for 12–24 weeks. Primary
outcome was pathological complete response (pCR). In EGF104900, 296 women with advanced disease were randomized to re-
ceive either lapatinib alone or lapatinib plus trastuzumab. Progression-free survival (PFS), overall response rate (ORR), and
overall survival (OS) were evaluated.
Results: A total of 305 patients with early and 117 patients with advanced HER2-positive disease were analyzed. In early dis-
ease, HER2-E represented 83.8% and 44.7% of ERBB2-high and ERBB2-low tumors, respectively. Following lapatinib and trastu-
zumab, the HER2-E and ERBB2 (HER2-E/ERBB2)-high group showed a higher pCR rate compared to the rest (44.5%, 95% confi-
dence interval [CI]¼35.4% to 53.9% vs 11.6%, 95% CI¼6.9% to 18.0%; adjusted odds ratio [OR] ¼ 6.05, 95% CI¼3.10 to 11.80,
P< .001). Similar findings were observed with neoadjuvant trastuzumab and pertuzumab (pCR rate of 66.7% in HER2-E/ERBB2-
high, 95% CI¼22.3% to 95.7% vs 14.7% in others, 95% CI¼4.9% to 31.1%; adjusted OR¼11.60, 95% CI ¼ 1.66 to 81.10, P¼ .01). In
the advanced setting, the HER2-E/ERBB2-high group was independently associated with longer PFS (hazard ratio [HR]¼0.52,
95% CI ¼ 0.35 to 0.79, P< .001); higher ORR (16.3%, 95% CI¼8.9% to 26.2% vs 3.7%, 95% CI¼0.8% to 10.3%, P¼ .02); and longer
OS (HR¼0.66, 95% CI¼0.44 to 0.97, P¼ .01).
Conclusions: Combining HER2-E subtype and ERBB2 mRNA into a single assay identifies tumors with high responsiveness to
HER2-targeted therapy. This biomarker could help de-escalate chemotherapy in approximately 40% of patients with HER2-
positive breast cancer.
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In patients with primary or metastatic HER2-positive breast
cancer, dual HER2-blockade without chemotherapy has shown
high activity in a subgroup of patients (1–9). In HER2-positive
disease, three neoadjuvant studies [TBCRC006 (3), TBCRC023 (4),
and SOLTI-PAMELA (5)] with a total of 314 patients with early
disease reported pathological complete response (pCR) rates in
the breast of approximately 30% following neoadjuvant trastu-
zumab and lapatinib. These results suggest that a subgroup of
patients with early-stage HER2-positive tumors might achieve
similar outcomes if treated with less or no chemotherapy.
However, beyond hormone receptor (HR) status, no predictive
biomarker of response to dual HER2-blockade has shown clini-
cal utility, to date.
HER2-positive disease is biologically heterogeneous when
assessed by gene expression profiling and can be divided into
four main intrinsic molecular subtypes (Luminal A, Luminal B,
HER2-enriched [HER2-E], and basal-like) (10–14). Among them,
the HER2-E subtype is characterized by higher expression of
ERBB2, ERBB2-amplicon genes (eg, GRB7), and receptor tyrosine
kinases including FGFR4 and EGFR, and lower expression of
luminal-related genes compared to the luminal subtypes. Thus,
HER2-E tumors are likely to have the highest activation of the
EGFR and/or HER2 pathway and the ones to benefit the most
from dual HER2 blockade.
The primary results from SOLTI-PAMELA revealed that the
HER2-E subtype within HER2-positive disease was associated
with a higher likelihood of achieving a pCR following neoadju-
vant trastuzumab and lapatinib (5). Interestingly, HR status was
not found to be statistically significantly associated with pCR
once intrinsic subtype and other clinical-pathological variables
were considered in multivariable analysis. Based on SOLTI-
PAMELA trial primary results, four questions needed to be
addressed: Can this finding be recapitulated in an independent
cohort? Can HER2-E subtype predict anti-HER2 sensitivity be-
yond single ERBB2 mRNA expression? Can these findings be ap-
plied to treatment with trastuzumab and pertuzumab without
chemotherapy? Can identification of anti-HER2 sensitivity pre-
dict survival outcome following dual HER2-blockade without
chemotherapy?
Methods
Study Designs and Participants
Baseline tumor samples from four HER2-positive neoadjuvant
studies [TBCRC006 (3), TBCRC023 (4), SOLTI-PAMELA (5), and
PER-ELISA (6)] were evaluated. The main inclusion criteria of the
four studies have been previously reported (3–6).
Briefly, in TBCRC006 and TBCRC023 (TBCRC006/023) and
SOLTI-PAMELA, all patients received lapatinib and trastuzumab.
Patients with HR-positive tumors received letrozole with or with-
out a luteinizing hormone-releasing hormone agonist according
to menopausal status. In SOLTI-PAMELA, premenopausal patients
received tamoxifen.
TBCRC006 was a single-arm phase II study of 66 patients
with stage II–III HER2-positive disease. Patients received
12 weeks of neoadjuvant treatment. TBCRC023 was a random-
ized, open-label phase II study of 128 patients with stage II–III
HER2-positive disease. Patients were randomized to receive 12
vs 24 weeks of neoadjuvant treatment. Finally, the SOLTI-
PAMELA was a single-arm phase II neoadjuvant study of 151
patients with stage I–III HER2-positive disease (5) treated for
18 weeks.
PER-ELISA was a single-arm phase II study of 64 patients
with stage I–III HER2-positive and HR-positive disease (6). After
diagnostic core-biopsy including baseline Ki67 evaluation, the
patients started letrozole for 2 weeks followed by a core-biopsy
for Ki67 central evaluation. Patients defined as molecular res-
ponders (Ki67 relative reduction >20% from baseline) started
therapy with the combination of letrozole, trastuzumab, and
pertuzumab. Trastuzumab and pertuzumab were administered
for five courses, and letrozole was continued until surgery.
Patients defined as molecular nonresponders discontinued
letrozole and received weekly paclitaxel combined with pertu-
zumab and trastuzumab. In this study, we only selected molec-
ular responders.
EGF104900 was a randomized phase III clinical trial (2, 9) of
296 women with HER2-positive advanced disease, who experi-
enced progression on prior trastuzumab-containing regimens,
to receive either lapatinib alone or lapatinib and trastuzumab.
The primary endpoint was progression-free survival (PFS).
Secondary endpoints included overall response rate (ORR) and
overall survival (OS).
The studies were undertaken in accordance with Good
Clinical Practice guidelines and the World Medical Association
Declaration of Helsinki. All patients provided written informed
consent. Approvals for the studies were obtained from indepen-
dent ethics committees. This study is reported according to
REMARK recommendations (15).
Tumor Samples and Gene Expression
Methods for RNA extraction, quantification, quality assessment,
and gene expression analysis can be found in Supplementary
Methods (available online).
Outcomes
For all neoadjuvant studies, except PER-ELISA, the primary end-
point was pCR in the breast defined as the absence of invasive
neoplastic cells at microscopic examination of the primary tu-
mor at surgery (ypT0/Tis). The primary endpoint in PER-ELISA
was pCR in the breast and axilla. In EGF104900, the primary end-
point was PFS defined as the time from randomization until ob-
jective tumor progression or death. The secondary endpoints
included ORR (confirmed complete response plus partial re-
sponse) and OS (time from randomization until death because
of any cause).
Statistical Analysis
To compare distribution of variables between two groups, we
used the Fisher exact test. Proportions and 95% confidence in-
terval (CI) were also provided. Univariate and multivariable lo-
gistic regression analyses were performed to investigate the
association of each variable with pCR. Odds ratios (ORs) and
95% CIs were calculated for each variable. Monte Carlo cross-
validation (16) was conducted (see Supplementary Methods,
available online). Univariate and multivariable Cox proportional
hazard regression analyses were performed to investigate the
association of each variable with PFS or OS. The proportionality
assumption was tested through evaluation of Schoenfeld resid-
uals, which indicated a modest association with time (P¼ .046).
The PFS model was fit with an additional time-dependent strati-
fication variable to account for change in proportional hazards
that occurs after 3 months of follow-up. Hazard ratio estimates
from the early stratum of the model were in close agreement
with both the unstratified model and a model where outcomes
were censored at 3 months. The statistical significance level was
set to a two-sided a of 0.05. All statistical tests were two-sided.
Results
Clinical-Pathological Characteristics of the Lapatinib
and Trastuzumab Neoadjuvant Studies
Baseline tumor samples from a total of 265 of 314 patients
(84.4%) were gene expression profiled (Supplementary Figure 1,
available online). No major statistically significant clinical-
pathological differences were observed between the TBCRC006/
023 and SOLTI-PAMELA cohorts (Table 1). Overall, most patients
had tumor stage II (138 [52.1%]), clinically node-negative (160
[60.4%]), and HR-positive (147 [55.5%]) disease and were post-
menopausal (155 [58.5%]). A pCR in the breast was noted in 70 of
265 women (26.4%, 95% CI ¼ 21.2 to 32.2).
According to intrinsic molecular subtyping, most tumors
were identified as HER2-E (174 [65.7%]), followed by Luminal B (27
[10.2%]), Luminal A (26 [9.8%]), basal-like (21 [7.9%]), and normal-
like (17 [6.4%]) (Figure 1A). No statistically significant difference
in the percentage of HER2-E tumors was observed between the
TBCRC006/023 and SOLTI-PAMELA cohorts (P¼ .695). As expected,
Luminal A and B subtypes were only identified in HR-positive
disease, and most basal-like tumors were identified in HR-
negative disease (P< .001). However, HER2-E was identified in
both groups in a substantial proportion of patients (54.0% and
81.0% in HR-positive and HR-negative disease, respectively)
(Figure 1A).
HER2-Enriched Association with Response in TBCRC006/
023 Cohort
Twenty of 73 patients with the HER2-E subtype (27.4%, 95% CI ¼
17.6% to 39.1%) and 4 of 41 patients with non-HER2-E subtypes
(9.8%, 95% CI ¼ 2.7% to 23.1%) achieved a pCR at the time of sur-
gery (OR¼ 3.49, 95% CI¼ 1.10 to 11.05, P¼ .03) (data not shown).
No other clinical-pathological variable was statistically signifi-
cantly associated with pCR in the univariate or multivariable
model (data not shown), although the study was not powered
for this purpose.
ERBB2 mRNA Association with Response in the
SOLTI-PAMELA Cohort
A large range of ERBB2 mRNA expression was observed (ie, 14-
fold change between the lowest and highest expressing tumor).
The pCR rates of ERBB2 expression across tertiles (T) in SOLTI-
PAMELA (ie, T1–T3) were 8.2% (T1), 23.5% (T2), and 58.8% (T3)
(P< .001). The OR of the T2–T3 group for achieving a pCR was
7.88 (95% CI¼ 2.63–23.56, P< .001) compared to the T1 group.
The OR of the T3 group for achieving a pCR was 4.72 (95%
CI¼ 2.69 to 8.42, P< .001) compared to the T1–T2 group.
The ERBB2 expression cutoff to define T1 (ERBB2-low) vs
T2-T3 (ERBB2-high) in SOLTI-PAMELA was chosen based on its
higher OR compared to the T3 vs T1–T2 comparison (ie, OR ¼
Table 1. Patient demographics of the neoadjuvant cohorts at baseline*
Variable
TBCRC 006, TBCRC 023, SOLTI-PAMELA, All,
No. (%) No. (%) No. (%) No. (%)
No. 29 85 151 265
Age, y, mean (SD) 52.4 (10.0) 52.5 (11.2) 54.8 (12.9) 53.8 (12.2)
Menopausal status
Premenopausal 12 (41.4) 37 (43.5) 61 (40.4) 110 (43.0)
Postmenopausal 17 (58.6) 48 (56.5) 90 (59.6) 155 (57.0)
Tumor stage
T1 1 (3.4) 2 (2.4) 60 (39.7) 63 (23.8)
T2 10 (34.5) 49 (57.6) 79 (52.3) 138 (52.1)
T3–T4 18 (62.1) 34 (40.0) 12 (7.9) 64 (24.2)
Nodal status
Negative 10 (34.5) 52 (61.2) 98 (64.9) 160 (60.4)
Positive 17 (58.6) 31 (36.5) 53 (35.1) 101 (38.1)
Missing 2 (6.9) 2 (2.4) NA 4 (1.5)
Treatment duration
12 weeks 29 (100.0) 31 (36.5) NA 60 (22.6)
18 weeks NA NA 151 (100.0) 151 (57.0)
24 weeks NA 54 (63.5) NA 54 (20.4)
Hormone receptor
Positive 19 (65.5) 51 (60.0) 77 (51.01) 147 (55.5)
Negative 10 (34.5) 34 (40.0) 74 (49.0) 118 (44.5)
PAM50
Luminal A NA 4 (4.7) 22 (14.6) 26 (9.8)
Luminal B 4 (13.8) 7 (8.2) 16 (10.6) 27 (10.2)
HER2-E 22 (75.8) 51 (60.0) 101 (66.9) 174 (65.6)
Basal-like 1 (3.4) 11 (12.9) 9 (5.9) 21 (7.9)
Normal-like 2 (6.9) 12 (14.1) 3 (2.0) 17 (6.4)
pCR rate in the breast 7 (24.1) 17 (20.0) 46 (30.5) 70 (26.4)
*pCR ¼ pathological complete response; NA ¼ not applicable.
7.88, 95% CI ¼ 2.63 to 23.56 vs OR ¼ 4.72, 95% CI¼ 2.69 to 8.42).
To characterize the stability and expected performance of our
threshold-defining rule, we performed a Monte Carlo cross-
validation (16) (Supplementary Methods, available online).
Results of cross-validation demonstrated the stability of the
cutoff (interquartile range [IQR] ¼ 0.18) relative to the dynamic
range of ERBB2 expression (IQR¼ 2.22) (Supplementary Figure
2A, available online). The final cutoff determined from the com-
plete cohort and used throughout the article was very close to
the mean of all the selected cutoffs during cross-validation (dif-
ference¼ 0.02). Performance estimates of the chosen ERBB2 cut-
off resulted in 92% sensitivity, 45% specificity, 42% positive
predictive value, and 93% negative predictive value
(Supplementary Figure 2B, available online).
ERBB2 mRNA Association with Response in the
TBCRC006/023 Cohort
The derived cutoff value was applied in 114 tumor samples
from the TBCRC006/023 cohort blinded from clinical data. The
pCR rates in T1 and T2-T3 were 8.3% (95% CI¼ 2.3% to 20.0%)
and 30.3% (95% CI¼ 19.6% to 42.9%, P< .001). The OR of the
T2–T3 group for achieving a pCR was 4.78 (95% CI¼ 1.51 to 15.11,
P¼ .008) compared to the T1 group (data not shown).
Analyses in the Lapatinib and Trastuzumab Combined
Neoadjuvant Cohort
HER2-E subtype was found statistically significantly associated
with pCR compared to non-HER2-E (35.1% vs 9.9%; OR¼ 4.92,
95% CI¼ 2.31 to 10.50, P< .001) (data not shown). At the same
time, the ERBB2-high group (defined as ERBB2 expression above
T1 [percentile 33rd] in SOLTI-PAMELA) was also found to be
statistically significantly associated with pCR compared to the
ERBB2-low group (36.1% vs 8.2%; OR¼ 6.51, 95% CI¼ 2.96 to
14.31, P< .001).
Like previous studies, a statistically significant higher ERBB2
mRNA expression was found in HER2-E disease compared to
non-HER2-E disease. However, a large range of ERBB2 expres-
sion was observed within HER2-E and non-HER2-E subtypes,
and overlap between the two groups was also evident
(Figure 1B). Indeed, the proportion of HER2-E disease within
ERBB2-high and ERBB2-low groups was 83.8% and 44.7%, respec-
tively (P < .001) (Figure 1C). Thus, although there was a clear re-
lationship between HER2-E and ERBB2 levels, the discordance
rate at the individual level was 21.1% (56 of 265).
Previous data have suggested that HER2-E subtype and ERBB2
levels should not be considered the same and that a combination
of both allows better identification of anti-HER2 sensitivity than
either one alone. To test it, we evaluated the pCR rates when
samples are classified by subtype (ie, HER2-E vs non-HER2-E) and
ERBB2 levels (ie, ERBB2-low and ERBB2-high). The HER2-E and
ERBB2 (HER2-E/ERBB2)-high group represented 44.9% of all sam-
ples. According to this classification, HER2-E/ERBB2-high tumors
showed the highest pCR rate (44.5%, 95% CI¼ 35.4% to 53.9%), fol-
lowed by non-HER2-E/ERBB2-high (16.1%, 95% CI ¼ 5.3% to
34.1%), HER2-E/ERBB2-low (10.8%, 95% CI ¼ 3.2% to 24.9%), and
non-HER2-E/ERBB2-low (6.7%, 95% CI ¼ 2.3% to 14.8%) groups
(Supplementary Figure 3, available online). The HER2-E/ERBB2-
high group showed a higher pCR rate compared to the rest
(44.5%, 95% CI¼ 35.4% to 53.9% vs 11.6%, 95% CI¼ 6.9% to 18.0%).
The OR of the HER2-E/ERBB2-high group for achieving a pCR was
6.09 (95% CI¼ 3.27 to 11.35, P< .001) compared to the rest
(Table 2). Finally, a multivariable analysis, including type of
study, confirmed the independent association of the HER2-E/
ERBB2-high group with pCR (adjusted OR¼ 6.05, 95% CI¼ 3.10 to





























































Figure 1. ERBB2 vs intrinsic subtypes in the combined neoadjuvant HER2-positive dataset (n¼265). A) Distribution of the intrinsic subtypes in all patients and based on
hormone receptor status. B) Distribution of tumor samples based on ERBB2 mRNA levels. C) Distribution of HER2-E subtype within ERBB2-high and ERBB2-low groups.
HER2-E¼ HER2-enriched; HR þ hormone receptor.
Independent Validation of the HER2-E/ERBB2-High
Biomarker in per-ELISA
To further test the ability of the combined biomarker to predict
pCR, 40 of 44 (91.0%) HER2-positive and HR-positive tumor sam-
ples treated with pertuzumab, trastuzumab, and letrozole in the
PER-ELISA trial (17) were profiled blinded from clinical data us-
ing the same exact assay and ERBB2 cut point (Supplementary
Table 1, available online). The proportion of HER2-E disease
within the ERBB2-high and ERBB2-low groups was 46.2% (6 of
13) and 18.5% (5 of 27), respectively. The discordance rate at the
individual level was 30.0% (12 of 40). A total of 6 (15.0%) and 34
(85.0%) samples were HER2-E/ERBB2-high and others, respec-
tively. The pCR rate of HER2-E/ERBB2-high was 66.7% (95%
CI¼ 22.3% to 95.7%, 4 of 6), and the pCR rate of the others group
was 14.7% (95% CI¼ 4.9% to 31.1%, 5 of 34). The OR of the HER2-
E/ERBB2-high group for achieving a pCR was 11.60 (95% CI¼ 1.66
to 81.10, P¼ .01) compared to the other groups. No other
clinical-pathological variable was statistically significantly as-
sociated with pCR, although the study was not powered for this
purpose.
Independent Validation of the HER2-E/ERBB2-High
Biomarker in EGF104900
To test the ability of the combined biomarker to predict survival
outcome, 117 (39.5%) of tumor samples from the EGF104900 trial
were profiled blinded from clinical data using the same exact
assay and ERBB2 cut point as in the previous studies
(Supplementary Figure 5, available online). Subtype distribution
was 58.2% HER2-E, 15.3% basal-like, 10.2% Luminal B, 2.3%
Luminal A, and 14.1% normal-like. Within ERBB2-high and
ERBB2-low, 70.8% and 31.0% of tumors were HER2-E, respectively.
The PAM50 population retained similar clinical-pathological fea-
tures and survival outcomes as the original trial population
(Supplementary Table 2, available online).
The HER2-E/ERBB2-high group represented 48.0% of all sam-
ples. The adjusted PFS hazard ratio of the HER2-E/ERBB2-high
group vs others was 0.52 (95% CI¼ 0.35 to 0.79, P< .001). Median
PFS of the HER2-E/ERBB2-high group was 3.5 months (95%
CI¼ 2.6 to 5.4 months) compared to 1.2 months (95% CI¼ 1.0 to
1.7 months) in others (Figure 2, A and C). The ORR of the HER2-E/
ERBB2-high group was statistically significantly higher com-
pared to others (ORR ¼ 16.3%, 95% CI¼ 8.9% to 26.2% vs 3.7%,
95% CI¼ 0.8% to 10.3%, P¼ .02). For OS, the adjusted hazard ratio
for HER2-E/ERBB2-high vs others was 0.66 (95% CI ¼ 0.44 to 0.97,
P¼ .01). Median OS was higher in the HER2-E/ERBB2-high group
(14.4 months; 95% CI ¼ 8.9 to 17.8 months) compared to others
(9.1 months; 95% CI ¼ 7 to 11.3 months) (Figure 2, B and D).
Finally, the study was not powered to detect an interaction be-
tween HER2-E/ERBB2-high and the treatment arm in relation to
PFS or OS, and a statistically significant interaction effect was
not observed.
Distribution of the HER2-E/ERBB2-High Biomarker in
HER2-Positive Disease
To evaluate the proportion of patients with HER2-E/ERBB2-high
disease, we combined all the available data from the five trials,
305 patients with early and 117 patients with advanced HER2-
positive disease (Figure 3A, Supplementary Figure 6, available
online). Overall, HER2-E/ERBB2-high disease represented 43.6%
Table 2. Logistic regression model analyses of treatment pathological response in the combined neoadjuvant cohort
Variable No. pCR, %
Univariate Multivariable
OR (95% CI) P* OR (95% CI) P*
Trial
TBCRC 006 29 24.1 1.00 (Reference) — 1.00 (Reference) —
TBCRC 023 85 20.0 0.78 (0.29 to 2.14) .263 0.61 (0.19 to 2.03) .385
SOLTI-PAMELA 151 30.5 1.37 (0.55 to 3.45) .157 0.78 (0.24 to 2.51) .973
Tumor stage
T1–T2 201 30.3 1.00 (Reference) — 1.00 (Reference) —
T3–T4 64 14.1 0.38 (0.17 to 0.81) .012 0.32 (0.12 to 0.83) .019
Menopausal status
Premenopausal 110 29.1 1.00 (Reference) — 1.00 (Reference) —
Postmenopausal 155 24.5 0.79 (0.46 to 1.37) .406 0.73 (0.39 to 1.36) .32
Nodal status
Negative 160 30.6 1.00 (Reference) — 1.00 (Reference) —
Positive 101 19.8 0.56 (0.31 to 1.01) .055 0.55 (0.28 to 1.08) .081
Treatment duration
12 weeks 60 18.3 1.00 (Reference) — —
18 weeks 151 30.5 1.95 (0.93 to 4.09) .088 — —
24 weeks 54 24.1 1.41 (0.57 to 3.49) .976 — —
Hormone receptor —
Positive 147 19.0 1.00 (Reference) — 1.00 (Reference) —
Negative 118 35.6 2.35 (1.34 to 4.10) .003 1.58 (0.83 to 2.99) .1649
PAM50þERBB2
Others 146 11.6 1.00 (Reference) — 1.00 (Reference) —
HER2-E/ERBB2- high 119 44.5 6.09 (3.27 to 11.35) <.001 6.05 (3.10 to 11.80) <.001
*Univariate and multivariable logistic regression analyses were done to investigate the association of each variable with pathological complete response (pCR). Odds
ratios (ORs) and 95% confidence interval (CIs) were calculated for each variable. The statistical significance level was set to a two-sided a of 0.05. HER2-E ¼ HER2-
enriched.
of the patients with HER2-positive disease, being 68.1% in HR-
negative disease and 31.7% in HR-positive disease.
Discussion
In the SOLTI-PAMELA trial (5), the HER2-E subtype was associ-
ated with a higher probability of achieving a pCR than non-
HER2-E disease following dual HER2-blockade without chemo-
therapy. Here, we validated this same observation in an inde-
pendent dataset composed of 114 baseline tumor samples from
two TBCRC trials (ie, TBCRC006 and 023) (3, 4). In addition, the
combined analysis of the SOLTI-PAMELA and TBCRC studies
allowed us to evaluate the predictive value of HER2-E subtype
beyond ERBB2 mRNA levels. Furthermore, we tested the ability
of the biomarker (HER2-E/ERBB2-high) to predict response and
survival in the metastatic setting following anti-HER2 therapy
without chemotherapy in EGF104900. Overall, HER2-E is a con-
sistent biomarker of pathological response following lapatinib
and trastuzumab, and both HER2-E and ERBB2 mRNA levels pro-
vide additional information from each other, and their combi-
nation into a single variable is better. To our knowledge, this is
the first study to report that a combined score based on two dif-
ferent mRNA-based variables tracking the HER2 signaling path-
way can identify high anti-HER2 sensitivity.
At first glance, the lack of high concordance between HER2-E
subtype and ERBB2 levels might seem counterintuitive.
However, approximately 35% of HER2-E tumors are HER2-
negative by standard American Society of Clinical Oncology
(ASCO) and College of American Pathologists (CAP) criteria (14).
Thus, both variables provide different and complementary in-
formation. Although a HER2-E profile might indicate the level of
activation of the HER2 and/or EGFR downstream signaling path-
way, ERBB2 mRNA levels ultimately determine the amount of
target present in the tumor cells. Thus, tumors that have high
expression of the main drug target and high activation of the
pathway (ie, ERBB2-high and HER2-E) are potentially the tumors
most “HER2-addicted” and most sensitive to anti-HER2-targeted
therapies (Figure 3B). Interestingly, tumors that meet only one
criterion (ie, the drug target is highly expressed but the down-
stream signaling pathway is lowly activated, or vice versa) have
an anti-HER2 sensitivity that is very similar to non-HER2-E/
ERBB2-low disease. This could help explain the variable re-
sponse to HER2-targeted therapy in HER2-positive tumors de-
fined by the ASCO/CAP criteria (14). Hence, further studies to
elucidate the driver(s) of the HER2-E subtype within HER2-
negative disease (18–20) and the non-HER2-E subtype within
HER2-positive disease could, in the future, better refine thera-
peutic options in breast cancer beyond current methods.
The ultimate goal of TBCRC006/023 (3, 4), PER-ELISA (6), and
SOLTI-PAMELA (5) studies is the promised land of nonchemo-
therapy in early HER2-positive disease. The combination of
anti-HER2 doublets with optimal chemotherapy regimens is
providing pCR rates in the range of 60%, increasing up to 75% in
HER2-positive and HR-negative tumors (21–25). The approxi-
mate 45% pCR rate in our study for the HER2-E/ERBB2-high
group is still far from this result. However, weekly paclitaxel
plus trastuzumab, a well-accepted regimen for patients with
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Figure 2. HER2-E/ERBB2-high biomarker in the EGF104900 trial of advanced HER2-positive breast cancer. A) Progression-free survival (PFS). B) Overall survival (OS). C)
PFS according to treatment arm. D) OS according to treatment arm. Estimates of PFS and OS were from Kaplan–Meier curves and tests of differences by two-sided log-
rank test. HER2-E ¼ HER2-enriched; HER2-E/ERBB2-high ¼ HER2-enriched and ERBB2-high group; T ¼ trastuzumab; L ¼ lapatinib.
stage I HER2-positive disease (26), has provided pCR rates rang-
ing from 29% to 46% (7, 10, 27). Our result suggests that a statis-
tically significant fraction of patients with HER2-positive
tumors may not need chemotherapy at all. If these patients
could be identified before the start of treatment, optimal re-
sponse could potentially be achieved with HER2-targeted ther-
apy alone. Although dual anti-HER2 blockage without
chemotherapy is still an exploratory approach, the molecular
HER2-E profile, together with ERBB2 mRNA levels, may be a
helpful tool to guide patients with sensitive tumors to nonche-
motherapy or less chemotherapy. Future, well-designed pro-
spective clinical trials should help establish the clinical utility of
the combined biomarker in specific scenarios and with particu-
lar cut points in both the early and the advanced settings.
Our study has several limitations. First, the clinical cohorts in
this study were powered for heterogeneous primary endpoints,
which have been evaluated in primary publications. The analysis
presented here used all available subjects from these studies, but
the lack of formal design through pre-planned analysis prohibits
inference of negative results. Instead, we focus our tests on varia-
bles with high precedent in these cohorts, namely, ERBB2 expres-
sion and HER2-E subtype. Additionally, we restrict our inference
to statistically significant results, which are repeatably and inde-
pendently assessed across all cohorts in the study. Second, the
HER2-E subtype can be identified to date using the PAM50 stan-
dardized nCounter-based assay from tumor samples. Regarding
the ERBB2 gene, which is included in the PAM50 assay, we have
proposed a particular cut point to define high vs low based on ter-
tile expression. Although the nCounter platform allows the clini-
cal implementation of highly reproducible assays (28, 29), further
analytical validation is needed. Third, we assessed clinical effi-
cacy in the early-stage setting based on pCR rates instead of sur-
vival. In addition, our data are mostly based on the combination
of trastuzumab plus lapatinib, and our findings will require con-
firmation in additional studies that test the combination of tras-
tuzumab plus pertuzumab. However, a retrospective ERBB2 qRT-
PCR mRNA-based analysis of 102 baseline tumor samples from
the chemotherapy-free arm of the NeoSphere neoadjuvant HER2-
positive trial with trastuzumab and pertuzumab showed pCR
rates in ERBB2-high and ERBB2-low groups (using median expres-
sion as the cutoff) of 23.4% and 10.9%, respectively (30). Fourth,
other promising molecular biomarkers have not been researched
in this study. Finally, several studies have suggested that consti-
tutive activation of the PI3K and AKT pathway is associated with
anti-HER2 resistance (31–33).
Our study establishes the potential clinical validity of the
HER2-E subtype and ERBB2 mRNA levels to predict anti-HER2
sensitivity. Our findings should now be externally validated,
and research groups from the National Clinical Trial Network in
the United States are now actively discussing the adoption of
standardized and analytically validated assays to allow the pro-
spective testing of this approach as an enrichment strategy for
the primary endpoint in prospective trials for early-stage HER2-
positive disease.
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